233 related articles for article (PubMed ID: 23640178)
21. Poor responders to bevacizumab pharmacotherapy in age-related macular degeneration and in diabetic macular edema demonstrate increased risk for obstructive sleep apnea.
Nesmith BL; Ihnen M; Schaal S
Retina; 2014 Dec; 34(12):2423-30. PubMed ID: 25062438
[TBL] [Abstract][Full Text] [Related]
22. Resolution of diabetic papillopathy after a single intravitreal injection of ranibizumab.
Willerslev A; Munch IC; Larsen M
Acta Ophthalmol; 2012 Aug; 90(5):e407-9. PubMed ID: 22268957
[No Abstract] [Full Text] [Related]
23. Combined therapy with intravitreal bevacizumab and posterior subtenon triamcinolone acetonide injection in diabetic macular oedema.
Kim HD; Kang KD; Choi KS; Rhee MR; Lee SJ
Acta Ophthalmol; 2014 Nov; 92(7):e589-90. PubMed ID: 24866832
[No Abstract] [Full Text] [Related]
24. Treatment of anti-vascular endothelial growth factor-resistant diabetic macular edema with dexamethasone intravitreal implant.
Lazic R; Lukic M; Boras I; Draca N; Vlasic M; Gabric N; Tomic Z
Retina; 2014 Apr; 34(4):719-24. PubMed ID: 23975006
[TBL] [Abstract][Full Text] [Related]
25. Dexamethasone Intravitreal Implant for Chronic Diabetic Macular Edema Resistant to Intravitreal Bevacizumab Treatment.
Totan Y; Güler E; Gürağaç FB
Curr Eye Res; 2016; 41(1):107-13. PubMed ID: 25610946
[TBL] [Abstract][Full Text] [Related]
26. Visual outcome after intravitreal bevacizumab depends on the optical coherence tomographic patterns of patients with diffuse diabetic macular edema.
Shimura M; Yasuda K; Yasuda M; Nakazawa T
Retina; 2013 Apr; 33(4):740-7. PubMed ID: 23222391
[TBL] [Abstract][Full Text] [Related]
27. Phacoemulsification with intravitreal bevacizumab and triamcinolone acetonide injection in diabetic patients with clinically significant macular edema and cataract.
Akinci A; Muftuoglu O; Altınsoy A; Ozkılıc E
Retina; 2011 Apr; 31(4):755-8. PubMed ID: 21124251
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of one intravitreal injection of bevacizumab in diabetic macular oedema.
Fang X; Sakaguchi H; Gomi F; Oshima Y; Sawa M; Tsujikawa M; Ikuno Y; Kamei M; Kusaka S; Tano Y
Acta Ophthalmol; 2008 Nov; 86(7):800-5. PubMed ID: 18547274
[TBL] [Abstract][Full Text] [Related]
29. OCT and cataract.
Falavarjani KG; Modarres M; Nikeghbali A
Ophthalmology; 2010 Apr; 117(4):849; author reply 849-50. PubMed ID: 20346827
[No Abstract] [Full Text] [Related]
30. Diabetic macular oedema in 2011: what are the options for refractory cystic oedema?
Wickremasinghe S
Clin Exp Ophthalmol; 2011; 39(7):595-7. PubMed ID: 22452678
[No Abstract] [Full Text] [Related]
31. Diagnostic and Therapeutic Challenges.
Uparkar MP; Kaul S; Manning DR; Mudvari SS
Retina; 2016 Mar; 36(3):641-4. PubMed ID: 26492386
[No Abstract] [Full Text] [Related]
32. Intravitreal injection of ranibizumab during cataract surgery in patients with diabetic macular edema.
Rauen PI; Ribeiro JA; Almeida FP; Scott IU; Messias A; Jorge R
Retina; 2012 Oct; 32(9):1799-803. PubMed ID: 22495327
[TBL] [Abstract][Full Text] [Related]
33. Refractive changes after pharmacologic resolution of diabetic macular edema.
Deák GG; Lammer J; Prager S; Mylonas G; Bolz M; Schmidt-Erfurth U;
Ophthalmology; 2014 May; 121(5):1054-8. PubMed ID: 24439462
[TBL] [Abstract][Full Text] [Related]
34. Spectral domain optical coherence tomography predictors of visual outcome in diabetic cystoid macular edema after bevacizumab injection.
Al Faran A; Mousa A; Al Shamsi H; Al Gaeed A; Ghazi NG
Retina; 2014 Jun; 34(6):1208-15. PubMed ID: 24368308
[TBL] [Abstract][Full Text] [Related]
35. Bevacizumab therapy for tamoxifen-induced crystalline retinopathy and severe cystoid macular edema.
Rahimy E; Sarraf D
Arch Ophthalmol; 2012 Jul; 130(7):931-2. PubMed ID: 22776935
[No Abstract] [Full Text] [Related]
36. Comparing aflibercept, bevacizumab, and ranibizumab for DME: analysis of DRCR Protocol T.
Wykoff CC; Hariprasad SM
Ophthalmic Surg Lasers Imaging Retina; 2015 Mar; 46(3):302-5. PubMed ID: 25835307
[No Abstract] [Full Text] [Related]
37. Intravitreal bevacizumab plus grid laser photocoagulation or intravitreal bevacizumab or grid laser photocoagulation for diffuse diabetic macular edema: results of the Pan-american Collaborative Retina Study Group at 24 months.
Arevalo JF; Lasave AF; Wu L; Diaz-Llopis M; Gallego-Pinazo R; Alezzandrini AA; Berrocal MH;
Retina; 2013 Feb; 33(2):403-13. PubMed ID: 23222389
[TBL] [Abstract][Full Text] [Related]
38. Bevacizumab (Avastin) for diabetic macular edema in previously vitrectomized eyes.
Yanyali A; Aytug B; Horozoglu F; Nohutcu AF
Am J Ophthalmol; 2007 Jul; 144(1):124-6. PubMed ID: 17601433
[TBL] [Abstract][Full Text] [Related]
39. Distribution of intraretinal exudates in diabetic macular edema during anti-vascular endothelial growth factor therapy observed by spectral domain optical coherence tomography and fundus photography.
Pemp B; Deák G; Prager S; Mitsch C; Lammer J; Schmidinger G; Scholda C; Schmidt-Erfurth U; Bolz M;
Retina; 2014 Dec; 34(12):2407-15. PubMed ID: 25062440
[TBL] [Abstract][Full Text] [Related]
40. Effect of intravitreal bevacizumab based on optical coherence tomography patterns of diabetic macular edema.
Kim M; Lee P; Kim Y; Yu SY; Kwak HW
Ophthalmologica; 2011; 226(3):138-44. PubMed ID: 21822008
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
